Four promising venture companies selected by the Korea Development Institute, challenge to develop innovative new drugs through data convergence and partnerships.

21-06-29

While Biogen's aducanumab received product approval from the US Food and Drug Administration (FDA) for the first time as a treatment for Alzheimer's disease, promising domestic venture companies are also in the midst of developing more effective and safer new drugs for brain-related diseases.

According to the biopharmaceutical industry on the 28th, the Korea Health Industry Development Institute selected and introduced four promising companies among bio ventures that are actively developing brain-related treatments such as dementia.

Neuroventi is developing treatments focusing on ADHD, autism, and developmental disorders. It received Siris A investment from Hyundai Venture and Medytox, and plans to conduct joint research and CRO research with external partners in the future.

CEO Shin Chan-young said, "We discovered a hypothesis base for pathological mechanisms through mechanism research using big data and AI, and we have in-house animal models for in vitro, in vivo, toxicity tests, It is possible to conduct both research and efficacy search,” he said.

"Currently preparing for phase 2 clinical trials, multi-target A02 and synthetic new drug 00X are representative pipelines," he said. subject to conditional permission.”

A02 is an autism treatment that improves sociality and behavior by acting on dopamine and serotonin. A patent has been applied for as a drug used in clinical practice. As it is being used to treat Parkinson's disease in some countries, phase 2 clinical trials will be conducted by drug re-creation.

CEO Shin said, "If drug development succeeds, there is a high possibility of becoming a global company as successful as Shire in England. However, foreign big pharmas are also conducting research and development, so we have to work harder."